Gapping up
In reaction to strong earnings/guidance: FINL +6.7%, NKE +3.8%
M&A news: PVA +2.6% (rumors yday of BP for PVA), HUM +1% (cont M&A spec)
Other news: GIGM +16.3% (to acquire a 70% equity interest in Strawberry Cosmetics Holding for ~$93.1 mln), CUR +10.8% (reports preclinical data on its genetically modified HK532-IGF-1 stem cells ), ABIO +8.3% (RA Capital Management disclosed 9.0% passive stake in 13G filing; Venrock Healthcare Capital Partners disclosed a 17.1% passive stake), VISI+6.4% (announced that Ron Kochman has resigned, effective immediately, as President and CEO; Board appoints Michael Dean, Volt's current Chairman, as Interim President and CEO), VNCE +3.7% (announces Mark Brody has been appointed interim CFO, replaces Lisa Klinger who resigns effective immediately ), DHR +2.8% (announced amendment and extension by one day of split-off exchange offer in connection with NetScout transaction), FOLD +2.5% (announces Galafold Marketing Authorization Application validated by European Medicines Agency ), VRTX +2.5% (higher following positive mention on CNBC's Fast Money ahead of co's July 5 PDUFA date for Orkambi for the treatment of cystic fibrosis), AEHR +2% (announced $1.7 mln follow-on order for ABTS burn-in and test systems from leading IC manufacturer), SKY +1.9% (Board named Richard W. Florea as new President and CEO), SWHC +1.7% (Board authorizes $50 mln stock repurchase plan)
Analyst comments: HRTX +3.3% (initiated with an Outperform at Cowen; $40 ), KFRC +2.3% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey ), TACO +2% (initiated with a Outperform at Wedbush), THC +1.9% (upgraded to Outperform from Market Perform at Wells Fargo), HCA +1.1% (upgraded to Outperform from Market Perform at Wells Fargo), CYH+0.9% (upgraded to Buy at Mizuho; tgt raised to $83.90), FTNT +0.6% (initiated with an Overweight at Barclays)
In reaction to strong earnings/guidance: FINL +6.7%, NKE +3.8%
M&A news: PVA +2.6% (rumors yday of BP for PVA), HUM +1% (cont M&A spec)
Other news: GIGM +16.3% (to acquire a 70% equity interest in Strawberry Cosmetics Holding for ~$93.1 mln), CUR +10.8% (reports preclinical data on its genetically modified HK532-IGF-1 stem cells ), ABIO +8.3% (RA Capital Management disclosed 9.0% passive stake in 13G filing; Venrock Healthcare Capital Partners disclosed a 17.1% passive stake), VISI+6.4% (announced that Ron Kochman has resigned, effective immediately, as President and CEO; Board appoints Michael Dean, Volt's current Chairman, as Interim President and CEO), VNCE +3.7% (announces Mark Brody has been appointed interim CFO, replaces Lisa Klinger who resigns effective immediately ), DHR +2.8% (announced amendment and extension by one day of split-off exchange offer in connection with NetScout transaction), FOLD +2.5% (announces Galafold Marketing Authorization Application validated by European Medicines Agency ), VRTX +2.5% (higher following positive mention on CNBC's Fast Money ahead of co's July 5 PDUFA date for Orkambi for the treatment of cystic fibrosis), AEHR +2% (announced $1.7 mln follow-on order for ABTS burn-in and test systems from leading IC manufacturer), SKY +1.9% (Board named Richard W. Florea as new President and CEO), SWHC +1.7% (Board authorizes $50 mln stock repurchase plan)
Analyst comments: HRTX +3.3% (initiated with an Outperform at Cowen; $40 ), KFRC +2.3% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey ), TACO +2% (initiated with a Outperform at Wedbush), THC +1.9% (upgraded to Outperform from Market Perform at Wells Fargo), HCA +1.1% (upgraded to Outperform from Market Perform at Wells Fargo), CYH+0.9% (upgraded to Buy at Mizuho; tgt raised to $83.90), FTNT +0.6% (initiated with an Overweight at Barclays)